The majority of patients with skin of color and scalp psoriasis who were treated with guselkumab achieved significant scalp clearance.

After adjusting for confounding factors, patients with CSU experience worse health outcomes and quality of life than patients with AD or PsO.

The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

President Trump ordered the reinstatement of the Presidential Fitness Test program, which tests children's athletic abilities.

The FDA is updating opioid safety labels to support treatment decisions based on the latest evidence to reduce misuse.

New research suggests that the survival benefits observed with different treatments for advanced melanoma vary according to the site of metastasis.

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of severe to very severe alopecia areata.

A growing number of women with chronic inflammatory diseases are continuing to use TNF inhibitors throughout pregnancy.

The risk for several ocular and auditory comorbidities is increased in children, adolescents, and adults with vitiligo compared with control patients.

More than half of pediatric patients with psoriasis or psoriasiform dermatitis had an anogenital or pharyngeal bacterial infection.

Patients with PWS who are treated with hemoporfin-mediated PDT have an increased prevalence of dermatitis and skin barrier damage.

An increase in the population burden of atopic dermatitis was associated with increased levels of environmental pollution and weather extremes.